The Role of Metallothionein in Chemotherapy with Platinum-Based Drugs
Author Information
Author(s): Krizkova Sona, Fabrik Ivo, Huska Dalibor, Adam Vojtech, Babula Petr, Hrabeta Jan, Eckschlager Tomas, Pochop Pavel, Darsova Denisa, Kukacka Jiri, Prusa Richard, Trnkova Libuse, Kizek Rene
Primary Institution: Mendel University in Brno
Hypothesis
This study aimed at investigating the interactions of metallothionein with cisplatin or carboplatin.
Conclusion
The study found that metallothionein levels significantly increase after the application of platinum-based therapeutics, which may contribute to tumor therapy resistance.
Supporting Evidence
- Metallothionein levels increased significantly in sensitive tumor cell lines after treatment with platinum-based drugs.
- Neuroblastoma cell lines showed different responses to cisplatin and carboplatin based on their resistance status.
- Carboplatin administration in rabbits led to a significant increase in metallothionein levels.
- Patients with retinoblastoma showed varying metallothionein levels after carboplatin treatment.
Takeaway
This study looks at how a protein called metallothionein interacts with cancer drugs like cisplatin and carboplatin, which can affect how well these drugs work.
Methodology
The study used an adsorptive transfer technique coupled with differential pulse voltammetry Brdicka reaction to analyze interactions between metallothionein and platinum-based drugs.
Potential Biases
Potential bias may arise from the small sample size of patient data.
Limitations
The study primarily focused on in vitro and in vivo experiments without extensive clinical trials.
Participant Demographics
The study included samples from rabbits and two retinoblastoma patients.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website